ToolGen Inaugurates Advanced Field Trial Facility in Osong, Completing 'Lab-to-Field' Commercialisation Platform for SAF Market
Cheongju, South Korea — ToolGen, Inc. (CEO Dr. Ryu Jong-Sang, KOSDAQ: 199800), a pioneer in CRISPR-Cas9 genome editing technology, has announced the inauguration of an advanced Genome-Edited Plant Field Testing Facility and the hosting of an Open Innovation Mini-Symposium at the Osong Innovation Circle, Cheongju, South Korea.
The newly inaugurated facility represents a significant step in translating genome editing innovation from the laboratory to commercial applications. Operating in full compliance with regulatory requirements, the facility will generate high-quality agronomic and performance data necessary to support product development, regulatory filings, and global commercialisation.
Completing the ‘From Lab to Land’ Commercialisation Platform
With the launch of this facility, ToolGen has established a comprehensive platform that integrates genome editing, superior trait development, field validation, and seed product development. The facility enables the evaluation of various plant species under real cultivation conditions. Field trials will focus on drought tolerance, herbicide tolerance, and enhanced seed oil composition to generate robust phenotypic datasets to validate plant performance and scalability for global industrial applications.
Positioning Growth in the Global SAF Feedstock Market
To meet the increasing global demand for Sustainable Aviation Fuel (SAF) feedstock, ToolGen is leveraging its new capabilities to develop a portfolio of genome-edited industrial oilseed crops, including pennycress, canola, carinata, camelina, Indian mustard, and castor bean.
By enhancing traits using CRISPR technology, ToolGen aims to increase potential yields and oil content, thereby providing sustainable feedstock without competing with conventional food production systems.
Building a Vertically Integrated Value Chain
Moving beyond the traditional licensing model, ToolGen is building a vertically integrated value chain that encompasses superior trait development, seed production, and downstream commercial partnerships, with a focus on Australia, Southeast Asia, and Europe.
“The Osong facility marks a significant milestone in the transformation of our seed business from research towards product-oriented commercialisation,” said Dan Sung, Executive Vice President of ToolGen’s Seed Business Division.
CEO Dr. Ryu Jong-Sang added: “We are strongly positioned to contribute to the future of bioenergy in Australia, Asia, and Europe. Recent patent proceedings in Europe do not affect ToolGen’s fundamental intellectual property position or our strategic commercial roadmap. ToolGen remains protected by a strong, independently developed next-generation patent portfolio, which serves as the foundation for our long-term competitive advantage and freedom to operate.”
Source: jawawa.id (https://jawawa.id/newsitem/toolgen-inaugurates-advanced-field-trial-facility-in-osong-completing-lab-to-field-commercialisation-platform-1781154016)
Originally published by Antara (Indonesian) (https://www.antaranews.com/berita/5603445/toolgen-resmikan-fasilitas-uji-lapangan-canggih-di-osong-lengkapi-platform-komersialisasi-dari-laboratorium-ke-lahan-untuk-pasar-saf), translated from Indonesian